Key result
Xiaoyao San significantly ameliorated high-fat diet-induced hepatic steatosis and liver injury in NAFLD rats by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways.
Why the study?
There is no approved pharmaceutical intervention for NAFLD, and while Xiaoyao San has shown therapeutic efficacy, its underlying mechanisms remain unclear.
Does Xiaoyao San improve nonalcoholic fatty liver disease in a high-fat diet-induced rat model?
Does Xiaoyao San improve nonalcoholic fatty liver disease in a high-fat diet-induced rat model?
Xiaoyao San improves nonalcoholic fatty liver disease in a rat model by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Xiaoyao San in rat NAFLD; leaves open human translation pending clinical trials.
Nonalcoholic Fatty Liver Disease (NAFLD) is characterized by excessive lipid accumulation in hepatocytes and is closely associated with metabolic disturbances such as obesity, dyslipidemia, and insulin resistance. Despite its increasing prevalence and potential progression to severe liver conditions, there is currently no approved pharmaceutical intervention for NAFLD. Traditional Chinese Medicine (TCM) formulations, such as Xiaoyao San (XYS), have shown therapeutic efficacy in treating NAFLD, but the underlying mechanisms remain unclear. This study employed a multi-omics approach to elucidate the therapeutic mechanisms of XYS in NAFLD. A rat model of NAFLD was established using a high-fat diet (HFD). The chemical constituents of XYS were analyzed using UPLC-MS/MS. Transcriptomics and proteomics analyses were performed to identify potential biological targets and signaling pathways involved in the therapeutic effects of XYS. The results were validated using ELISA and Western blotting. UPLC-MS/MS identified 225 prototype chemical components of XYS in the blood. XYS significantly reduced body weight, liver index, and Lee's index in NAFLD model rats. It ameliorated HFD-induced hepatic steatosis, down-regulated serum levels of ALT, AST, GGT, TG, TC, LDL-C, FBG, IL-1β, IL-6, TNF-α, and ROS, and up-regulated HDL-C levels. Transcriptomics and proteomics analyses revealed that XYS modulated key signaling pathways, including cAMP, TGF-β, NF-κB, and necroptosis. Specifically, XYS down-regulated the expressions of NF-κB, p-NF-κB, FOXO1, TGF-β1, RIP3, and p-MLKL, while up-regulating cAMP, PKA, p-PKA, and PPARα. XYS improves NAFLD by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways. This study provides a comprehensive understanding of the molecular mechanisms underlying the therapeutic effects of XYS in NAFLD and supports its potential as a novel therapeutic intervention for this condition.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied Nonalcoholic Fatty Liver Disease (NAFLD) (n=24). Xiaoyao San (XYS) vs. Normal saline was evaluated. Xiaoyao San significantly ameliorated high-fat diet-induced hepatic steatosis and liver injury in NAFLD rats by regulating the cAMP/PKA-mediated PPARα, FOXO1, and NF-κB signaling pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: